Company / SG&A per Share
Janux Therapeutics, Inc. SG&A per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.67
FY2025
5-year range
$0.44 / $0.76
FY2021-FY2025
Trend
-11.7%
vs FY2024
Sector context
#150 of 208
Health Care
What the data says
At $0.67, Janux Therapeutics, Inc.'s sg&a per share ranks #59 of 208 in the Health Care sector. Increased from $0.59 to $0.67 over the past 2 years.
Based on SEC 10-K filings.
0.67 in FY2025 with a 5-year CAGR of -19.3%.
Increased from $0.59 to $0.67 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +7.9%
- 5-Year CAGR
- -19.3%
- 10-Year CAGR
- -
Sector benchmark
#59 of 208 in Health CareTop 28% of 208This company $0.67 Sector average $29.78
▼
-97.7% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share decreased 11.7% year-over-year.
- Ranks #150 out of 208 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2020.
- Lowest sg&a per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.67 | -11.7% |
| FY2024 | $0.76 | +28.6% |
| FY2023 | $0.59 | +10.6% |
| FY2022 | $0.54 | +22.3% |
| FY2021 | $0.44 | -77.7% |
| FY2020 | $1.97 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026